Oveporexton, a novel first-in-class OX2R-selective agonist, shows promise for improving memory, attention, and executive function in individuals with narcolepsy type 1.
Collaboration aims to accelerate the development of treatments for chronic kidney disease (CKD) and other conditions Rectify ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback